Does the availability of influenza vaccine at prenatal care visits and of immediate vaccination improve vaccination coverage of pregnant women?


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 19 12 2018
accepted: 22 07 2019
entrez: 2 8 2019
pubmed: 2 8 2019
medline: 10 3 2020
Statut: epublish

Résumé

Although vaccination against influenza is recommended for pregnant women in France because it exposes them to a risk of death and severe respiratory complications, their vaccination coverage in 2016 was estimated at 7%. This study's principal objective was to assess the association between the availability of influenza vaccination at prenatal care visits and vaccination coverage. This multicenter survey took place in 3 Paris-area public hospital (AP-HP) maternity wards (A, B, and C). Only maternity ward A offered the vaccine and vaccination without charge at prenatal visits. Data were collected from parturients during 10 days in January 2017 by a self-administered anonymous questionnaire. Data from 248 women showed overall vaccination coverage of 19.4% (48/248): 35.4% (46/130) in maternity unit A, 2.7% (2/75) in B, and 0% (0/43) in C (P<0.01). After adjustment for socio-demographic characteristics, women at maternity ward A were significantly more likely to be vaccinated than those at B and C (aOR 25.52, 95%CI [5.76-113.10]). Other factors significantly associated with higher vaccination coverage were the mother's French birth (aOR 2.37 CI [1.03-5.46]) and previous influenza vaccination (aOR 3.13, 95%CI [1.25-7.86]). Vaccinated women generally considered they had received adequate information (aOR 4.15 CI [2.10-8.22]), principally from the professional providing their prenatal care. Nonvaccination was attributed to the absence of an offer of vaccination (81.5%), fear of fetal side effects (59.5%), and inadequate information (51.4%). Our results show that availability of influenza vaccination, free of charge, at prenatal consultations at the maternity ward increases vaccination coverage significantly.

Identifiants

pubmed: 31369626
doi: 10.1371/journal.pone.0220705
pii: PONE-D-18-27502
pmc: PMC6675112
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0220705

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Am J Epidemiol. 2006 Mar 15;163(6):571-8
pubmed: 16443801
N Engl J Med. 2008 Oct 9;359(15):1555-64
pubmed: 18799552
Vaccine. 2009 Jun 19;27(30):4018-24
pubmed: 19389442
Obstet Gynecol. 2010 Apr;115(4):717-26
pubmed: 20308830
JAMA. 2010 Apr 21;303(15):1517-25
pubmed: 20407061
N Engl J Med. 2010 Apr 29;362(17):1644-6
pubmed: 20427817
J Am Geriatr Soc. 2010 Jul;58(7):1333-40
pubmed: 20533970
Health Technol Assess. 2010 Jul;14(34):109-82
pubmed: 20630123
Arch Pediatr Adolesc Med. 2011 Feb;165(2):104-11
pubmed: 20921345
J Obstet Gynaecol Can. 2010 Aug;32(8):745-8
pubmed: 21050505
Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S112-5
pubmed: 21345408
J Obstet Gynaecol Can. 2011 May;33(5):460-467
pubmed: 21639966
Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S1-3
pubmed: 21640228
Am J Obstet Gynecol. 2011 Jun;204(6 Suppl 1):S124-7
pubmed: 21640229
PLoS Med. 2011 May;8(5):e1000441
pubmed: 21655318
BMJ. 2011 Jun 14;342:d3214
pubmed: 21672992
PLoS One. 2011;6(6):e20900
pubmed: 21695074
Am J Obstet Gynecol. 2011 Nov;205(5):473.e1-9
pubmed: 21861964
Matern Child Health J. 2013 Jan;17(1):23-32
pubmed: 22297574
J Matern Fetal Neonatal Med. 2012 Sep;25(9):1800-9
pubmed: 22339083
Vaccine. 2012 Apr 16;30(18):2892-9
pubmed: 22374374
N Engl J Med. 2013 Jan 24;368(4):333-40
pubmed: 23323868
Obstet Gynecol. 2013 Mar;121(3):519-25
pubmed: 23635613
Presse Med. 2013 Nov;42(11):1453-60
pubmed: 23683385
Vaccine. 2013 Oct 25;31(45):5281-8
pubmed: 24016814
Vaccine. 2014 Aug 6;32(36):4602-13
pubmed: 24996123
N Engl J Med. 2014 Sep 4;371(10):918-31
pubmed: 25184864
Expert Opin Drug Saf. 2014 Dec;13(12):1709-20
pubmed: 25363497
Clin Infect Dis. 2015 Mar 1;60(5):e11-9
pubmed: 25409473
Hum Vaccin Immunother. 2015;11(3):713-8
pubmed: 25714987
J Womens Health (Larchmt). 2015 May;24(5):394-402
pubmed: 25874550
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Vaccine. 2015 Nov 25;33(47):6420-9
pubmed: 26320417
Women Birth. 2016 Oct;29(5):423-429
pubmed: 26879102
Lancet Infect Dis. 2016 Sep;16(9):1026-1035
pubmed: 27261067
Vaccine. 2016 Jul 25;34(34):3942-9
pubmed: 27317458
PLoS One. 2016 Jul 08;11(7):e0159087
pubmed: 27391098
EBioMedicine. 2016 Oct;12:295-301
pubmed: 27658738
BMC Infect Dis. 2017 Jan 9;17(1):48
pubmed: 28068918
Lancet Infect Dis. 2017 Sep;17(9):981-989
pubmed: 28522338
Public Health Rep. 2017 Jul/Aug;132(4):451-454
pubmed: 28586623
Vaccine. 2018 Oct 22;36(44):6473-6479
pubmed: 28811050
MMWR Morb Mortal Wkly Rep. 2017 Sep 29;66(38):1016-1022
pubmed: 28957044
Vaccine. 2018 Mar 20;36(13):1796-1800
pubmed: 29395531
Vaccine. 2018 Mar 27;36(14):1801-1803
pubmed: 29506923
Hum Vaccin Immunother. 2018 Jul 3;14(7):1558-1565
pubmed: 29641945
Hum Vaccin Immunother. 2018 Jul 3;14(7):1573-1579
pubmed: 29863958
PLoS One. 2018 Jun 14;13(6):e0197867
pubmed: 29902184
Med Mal Infect. 2019 Feb;49(1):34-37
pubmed: 30409542
Vaccine. 2019 Feb 8;37(7):984-990
pubmed: 30655175
PLoS One. 2019 Mar 28;14(3):e0214538
pubmed: 30921421

Auteurs

Vivien Alessandrini (V)

Maternité Port-Royal, Université Paris Descartes, Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.
DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.

Olivia Anselem (O)

Maternité Port-Royal, Université Paris Descartes, Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.
DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.

Aude Girault (A)

Maternité Port-Royal, Université Paris Descartes, Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.
DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.

Laurent Mandelbrot (L)

DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.
Maternité Louis-Mourier, Université Diderot Paris 7, Hôpitaux Universitaires Paris Nord Val-de-Seine, Assistance Publique Hôpitaux de Paris, Colombes, France.

Dominique Luton (D)

DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.
Maternité Bichat-Claude Bernard, Université Diderot Paris 7, Hôpitaux Universitaires Paris Nord Val-de-Seine, Assistance Publique Hôpitaux de Paris, Paris, France.

Odile Launay (O)

DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Inserm, CIC 1417, AP-HP, Groupe Hospitalier Cochin-Broca-Hôtel-Dieu, Centre d'investigation Clinique Cochin-Pasteur,Paris, France.

François Goffinet (F)

Maternité Port-Royal, Université Paris Descartes, Groupe hospitalier Cochin Broca Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, Paris, France.
DHU Risques et Grossesse, PRES Sorbonne Paris Cité, Paris, France.
Unité INSERM U953, Recherche épidémiologique en santé périnatale et santé des femmes et des enfants, UPMC, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH